Works by Sarayut Geater

Results: 20
    1

    Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis.

    Published in:
    Cancer Research & Treatment, 2023, v. 55, n. 1, p. 83, doi. 10.4143/crt.2021.1571
    By:
    • Byoung Chul Cho;
    • Dong-Wan Kim;
    • Ullas Batra;
    • Keunchil Park;
    • Sang-We Kim;
    • Cheng-Ta Yang;
    • Pei-Jye Voon;
    • Virote Sriuranpong;
    • K. Govind Babu;
    • Khalid Amin;
    • Yingbo Wang;
    • Paramita Sen;
    • Khemaies Slimane;
    • Sarayut Geater
    Publication type:
    Article
    2
    3

    Thailand, Songkhla.

    Published in:
    2021
    By:
    • Sriplung, Hutcha;
    • Geater, Sarayut Lucien;
    • Prechavitayakul, Paradee;
    • Tassanapitak, Cheamjit;
    • Bilheem, Surichai
    Publication type:
    Chart/Diagram/Graph
    4

    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 3, p. 266, doi. 10.1016/j.cllc.2024.03.003
    By:
    • Garon, Edward B.;
    • Byoung Chul Cho;
    • Luft, Alexander;
    • Alatorre-Alexander, Jorge;
    • Geater, Sarayut Lucien;
    • Dmytro Trukhin;
    • Sang-We Kim;
    • Ursol, Grygorii;
    • Hussein, Maen;
    • Louise Lim, Farah;
    • Cheng-Ta Yang;
    • Araujo, Luiz Henrique;
    • Haruhiro Saito;
    • Reinmuth, Niels;
    • Kohlmann, Milena;
    • Lowery, Caitlin;
    • Mann, Helen;
    • Peters, Solange;
    • Mok, Tony S.;
    • Johnson, Melissa L.
    Publication type:
    Article
    5

    Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

    Published in:
    Clinical Lung Cancer, 2022, v. 23, n. 8, p. 670, doi. 10.1016/j.cllc.2022.07.012
    By:
    • Myung-Ju Ahn;
    • Mendoza, Marvin Jonne L.;
    • Pavlakis, Nick;
    • Terufumi Kato;
    • Soo, Ross A.;
    • Dong-Wan Kim;
    • Chong Kin Liam;
    • Te-Chun Hsia;
    • Chee Khoon Lee;
    • Thanyanan Reungwetwattana;
    • Sarayut Geater;
    • Siu Hong Chan, Oscar;
    • Naiyarat Prasongsook;
    • Solomon, Benjamin J.;
    • Thi Thai Hoa Nguyen;
    • Toshiyuki Kozuki;
    • Chih-Hsin Yang, James;
    • Yi-Long Wu;
    • Shu Kam Mok, Tony;
    • Shao-Weng Tan, Daniel
    Publication type:
    Article
    6

    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC).

    Published in:
    Clinical Lung Cancer, 2021, v. 22, n. 4, p. 301, doi. 10.1016/j.cllc.2021.02.010
    By:
    • Garon, Edward B.;
    • Cho, Byoung Chul;
    • Reinmuth, Niels;
    • Lee, Ki Hyeong;
    • Luft, Alexander;
    • Ahn, Myung-Ju;
    • Robinet, Gilles;
    • Le Moulec, Sylvestre;
    • Natale, Ronald;
    • Schneider, Jeffrey;
    • Shepherd, Frances A.;
    • Garassino, Marina Chiara;
    • Geater, Sarayut Lucien;
    • Szekely, Zsolt Papai;
    • Van Ngoc, Tran;
    • Liu, Feng;
    • Scheuring, Urban;
    • Patel, Nikunj;
    • Peters, Solange;
    • Rizvi, Naiyer A.
    Publication type:
    Article
    7

    Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    Published in:
    2018
    By:
    • Wu, Yi-Long;
    • Sequist, Lecia V;
    • Tan, Eng-Huat;
    • Geater, Sarayut L;
    • Orlov, Sergey;
    • Zhang, Li;
    • Lee, Ki Hyeong;
    • Tsai, Chun-Ming;
    • Kato, Terufumi;
    • Barrios, Carlos H;
    • Schuler, Martin;
    • Hirsh, Vera;
    • Yamamoto, Nobuyuki;
    • O'Byrne, Kenneth;
    • Boyer, Michael;
    • Mok, Tony;
    • Peil, Barbara;
    • Märten, Angela;
    • Chih-Hsin Yang, James;
    • Paz-Ares, Luis
    Publication type:
    journal article
    8
    9
    10
    11
    12
    13

    Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).

    Published in:
    Patient, 2018, v. 11, n. 1, p. 131, doi. 10.1007/s40271-017-0287-z
    By:
    • Wu, Yi-Long;
    • Hirsh, Vera;
    • Sequist, Lecia;
    • Hu, Cheng-Ping;
    • Feng, Jifeng;
    • Lu, Shun;
    • Huang, Yunchao;
    • Schuler, Martin;
    • Mok, Tony;
    • Yamamoto, Nobuyuki;
    • O'Byrne, Kenneth;
    • Geater, Sarayut;
    • Zhou, Caicun;
    • Massey, Dan;
    • Märten, Angela;
    • Lungershausen, Juliane;
    • Yang, James
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20